199 related articles for article (PubMed ID: 24553398)
1. Second-generation tyrosine kinase inhibitors combined with stem cell transplantation in patients with imatinib-refractory chronic myeloid leukemia.
Zhao Y; Luo Y; Shi J; Cai Z; Huang H
Am J Med Sci; 2014 Jun; 347(6):439-45. PubMed ID: 24553398
[TBL] [Abstract][Full Text] [Related]
2. Imatinib combined with myeloablative allogeneic hematopoietic stem cell transplantation for advanced phases of chronic myeloid leukemia.
Luo Y; Zhao Y; Tan Y; Shi J; Han X; Zheng Y; Li L; He J; Xie W; Ye X; Cai Z; Lin M; Huang H
Leuk Res; 2011 Oct; 35(10):1307-11. PubMed ID: 21354617
[TBL] [Abstract][Full Text] [Related]
3. Second-generation tyrosine kinase inhibitors before allogeneic stem cell transplantation in patients with chronic myeloid leukemia resistant to imatinib.
Breccia M; Palandri F; Iori AP; Colaci E; Latagliata R; Castagnetti F; Torelli GF; Usai S; Valle V; Martinelli G; Rosti G; Foà R; Baccarani M; Alimena G
Leuk Res; 2010 Feb; 34(2):143-7. PubMed ID: 19481800
[TBL] [Abstract][Full Text] [Related]
4. Management of Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL).
Ottmann OG; Pfeifer H
Hematology Am Soc Hematol Educ Program; 2009; ():371-81. PubMed ID: 20008223
[TBL] [Abstract][Full Text] [Related]
5. Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure.
Jabbour E; Cortes J; Kantarjian HM; Giralt S; Jones D; Jones R; Giles F; Andersson BS; Champlin R; de Lima M
Blood; 2006 Aug; 108(4):1421-3. PubMed ID: 16601247
[TBL] [Abstract][Full Text] [Related]
6. Extended follow-up of patients treated with imatinib mesylate (gleevec) for chronic myelogenous leukemia relapse after allogeneic transplantation: durable cytogenetic remission and conversion to complete donor chimerism without graft-versus-host disease.
DeAngelo DJ; Hochberg EP; Alyea EP; Longtine J; Lee S; Galinsky I; Parekkedon B; Ritz J; Antin JH; Stone RM; Soiffer RJ
Clin Cancer Res; 2004 Aug; 10(15):5065-71. PubMed ID: 15297408
[TBL] [Abstract][Full Text] [Related]
7. Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up.
Palandri F; Castagnetti F; Testoni N; Luatti S; Marzocchi G; Bassi S; Breccia M; Alimena G; Pungolino E; Rege-Cambrin G; Varaldo R; Miglino M; Specchia G; Zuffa E; Ferrara F; Bocchia M; Saglio G; Pane F; Alberti D; Martinelli G; Baccarani M; Rosti G;
Haematologica; 2008 Dec; 93(12):1792-6. PubMed ID: 18838477
[TBL] [Abstract][Full Text] [Related]
8. Characterisation of extramedullary relapse in patients with chronic myeloid leukemia in advanced disease after allogeneic stem cell transplantation.
Ocheni S; Iwanski GB; Schafhausen P; Zander AR; Ayuk F; Klyuchnikov E; Zabelina T; Fiedler W; Schnittger S; Hochhaus A; Brümmendorf TH; Kröger N; Bacher U
Leuk Lymphoma; 2009 Apr; 50(4):551-8. PubMed ID: 19373652
[TBL] [Abstract][Full Text] [Related]
9. [Treatment efficacy of imatinib mesylate versus allogeneic hematopoietic stem cell transplantation for patients with chronic myeloid leukemia in chronic phase].
Gao GL; Xu N; Zhou X; Xiao YJ; Ding L; Lu QS; Wei YQ; Zhang Y; Xu D; Sun J; Liu QF; Liu XL
Zhonghua Yi Xue Za Zhi; 2013 Oct; 93(38):3035-9. PubMed ID: 24417923
[TBL] [Abstract][Full Text] [Related]
10. Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia.
Kantarjian HM; O'Brien S; Cortes JE; Giralt SA; Rios MB; Shan J; Giles FJ; Thomas DA; Faderl S; De Lima M; Garcia-Manero G; Champlin R; Arlinghaus R; Talpaz M
Blood; 2002 Sep; 100(5):1590-5. PubMed ID: 12176876
[TBL] [Abstract][Full Text] [Related]
11. Dasatinib as salvage therapy for steroid refractory and imatinib resistant or intolerant sclerotic chronic graft-versus-host disease.
Sánchez-Ortega I; Servitje O; Arnan M; Ortí G; Peralta T; Manresa F; Duarte RF
Biol Blood Marrow Transplant; 2012 Feb; 18(2):318-23. PubMed ID: 22068151
[TBL] [Abstract][Full Text] [Related]
12. A significant proportion of patients with chronic myeloid leukemia and suboptimal response according to European Leukemia Net criteria have excellent prognosis without treatment change.
Rohon P; Faber E; Divoka M; Rozmanova S; Friedecky D; Jarosova M; Indrak K
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2013 Jun; 157(2):181-8. PubMed ID: 22660209
[TBL] [Abstract][Full Text] [Related]
13. Imatinib mesylate (STI571) in preparation for allogeneic hematopoietic stem cell transplantation and donor lymphocyte infusions in patients with Philadelphia-positive acute leukemias.
Shimoni A; Kröger N; Zander AR; Rowe JM; Hardan I; Avigdor A; Yeshurun M; Ben-Bassat I; Nagler A
Leukemia; 2003 Feb; 17(2):290-7. PubMed ID: 12592325
[TBL] [Abstract][Full Text] [Related]
14. [Imatinib in combination with allogeneic hematopoietic stem cell transplantation improved the outcome of adult Philadelphia chromosome-positive acute lymphoblastic leukemia].
Cheng Z; Zhao L; Chen G; Wu D; Qiu H; Tang X; Fu C; Jin Z; Chen F; Xue S; Sun A
Zhonghua Xue Ye Xue Za Zhi; 2014 Feb; 35(2):114-9. PubMed ID: 24606651
[TBL] [Abstract][Full Text] [Related]
15. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial.
Mahon FX; Réa D; Guilhot J; Guilhot F; Huguet F; Nicolini F; Legros L; Charbonnier A; Guerci A; Varet B; Etienne G; Reiffers J; Rousselot P;
Lancet Oncol; 2010 Nov; 11(11):1029-35. PubMed ID: 20965785
[TBL] [Abstract][Full Text] [Related]
16. Long-term results of high-dose imatinib in children and adolescents with chronic myeloid leukaemia in chronic phase: the Italian experience.
Giona F; Putti MC; Micalizzi C; Menna G; Moleti ML; Santoro N; Iaria G; Ladogana S; Burnelli R; Consarino C; Varotto S; Tucci F; Messina C; Nanni M; Diverio D; Biondi A; Pession A; Locatelli F; Piciocchi A; Gottardi E; Saglio G; Foà R
Br J Haematol; 2015 Aug; 170(3):398-407. PubMed ID: 25891192
[TBL] [Abstract][Full Text] [Related]
17. Imatinib use either pre- or post-allogeneic hematopoietic cell transplantation (allo-HCT) does not increase cardiac toxicity in chronic myelogenous leukemia patients.
Burke MJ; Trotz B; Luo X; Weisdorf DJ; Baker KS; Wagner JE; Verneris MR
Bone Marrow Transplant; 2009 Aug; 44(3):169-74. PubMed ID: 19204709
[TBL] [Abstract][Full Text] [Related]
18. A population study showing that the advent of second generation tyrosine kinase inhibitors has improved progression-free survival in chronic myeloid leukaemia.
Francis S; Lucas C; Lane S; Wang L; Watmough S; Knight K; Bell J; Kaleel-Rahman M; Lee E; O'Brien D; Butt NM; Sadik W; De Soysa L; Seale JR; Salim R; Clark RE
Leuk Res; 2013 Jul; 37(7):752-8. PubMed ID: 23618689
[TBL] [Abstract][Full Text] [Related]
19. Management of chronic myeloid leukaemia in relapse following donor lymphocyte infusion induced remission: a retrospective study of the Clinical Trials Committee of the British Society of Blood & Marrow Transplantation (BSBMT).
Cummins M; Cwynarski K; Marktel S; Dazzi F; Cavenagh J; Clark RE; Holyoake TL; Milligan D; Parker A; Russell NH; Marks DI;
Bone Marrow Transplant; 2005 Dec; 36(12):1065-9. PubMed ID: 16247434
[TBL] [Abstract][Full Text] [Related]
20. Alpha-interferon with very-low-dose donor lymphocyte infusion for hematologic or cytogenetic relapse of chronic myeloid leukemia induces rapid and durable complete remissions and is associated with acceptable graft-versus-host disease.
Posthuma EF; Marijt EW; Barge RM; van Soest RA; Baas IO; Starrenburg CW; van Zelderen-Bhola SL; Fibbe WE; Smit WM; Willemze R; Falkenburg JH
Biol Blood Marrow Transplant; 2004 Mar; 10(3):204-12. PubMed ID: 14993886
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
